JRCT ID: jRCT2031230615
Registered date:01/02/2024
DAREON-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer
Basic Information
Recruitment status | Pending |
---|---|
Health condition(s) or Problem(s) studied | Histologically or cytologically confirmed ES-SCLC |
Date of first enrollment | 22/02/2024 |
Target sample size | 60 |
Countries of recruitment | United State,Japan,Spain,Japan,Poland,Japan,Switzerland,Japan,Germany,Japan,France,Japan,Belgium,Japan |
Study type | Interventional |
Intervention(s) | Part A - Administer BI 764532 in combination with SoC with platinum, etoposide, and anti-PD-L1 antibody. Part B - Administer BI 764532 in combination with different standard treatment regimens (chemotherapy and anti-PD-L1 antibodies). |
Outcome(s)
Primary Outcome | Part A - Dose escalation Primary endpoint: occurrence of dose-limiting toxicities (DLTs) in the MTD evaluation period Part B - Dose expansion Primary endpoint: occurrence of DLTs during the on-treatment period |
---|---|
Secondary Outcome | Part A - Dose escalation Secondary endpoints - Occurrence of DLTs during the on-treatment period Part B - Dose expansion Secondary endpoints - Objective response,defined as a best overall response of confirmed complete response or confirmed partial response according to RECIST1.1 from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up, or withdrawal of consent - Duration of response, defined as the time from first documented confirmed objective response until the earliest date of disease progression or death among patients with confirmed objective response |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | - Signed and dated written informed consent form in accordance with ICH-GCP and local legislation prior to any trial-specific procedures, sampling, or analyses - Patients must be eligible for platinum+etoposide + anti-PD-L1 regimen as first line SoC treatment: In Part A, patients must be eligible to receive carboplatin + etoposide + atezolizumab In Part B, patients must be eligible to receive etoposide, carboplatin or cisplatin, atezolizumab or durvalumab - Adequate liver, bone marrow, and renal function |
Exclude criteria | - Previous treatment with DLL3-targeting T cell engagers and cell therapies - Persistent toxicity from previous treatments that has not resolved to <=CTCAE Grade 1 (except for alopecia, CTCAE Grade 2 neuropathy, asthenia/fatigue, or Grade 2 endocrinopathies controlled by replacement therapy) - History of/active non-infectious pneumonitis/interstitial lung disease - Diagnosis of immunodeficiency, or systemic glucocorticoid therapy, or intake of any form of immunosuppressive therapy within 7 days prior to the first dose of BI 764532. Physiological replacement of steroids is allowed (glucocorticoid dose needed by a patient to maintain physiological steroid levels in the body) - Significant cardiovascular/cerebrovascular diseases (e.g. uncontrolled hypertension, unstable angina, history of infarction within past 6 months, congestive heart failure >NYHA II). - Women who are pregnant, nursing, or who plan to become pregnant while in the trial |
Related Information
Primary Sponsor | Tsunoda Toru |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Nobuko Yamada |
Address | ThinkPark Tower 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017, Japan Tokyo Japan 141-6017 |
Telephone | +81-120-189-779 |
medchiken.jp@boehringer-ingelheim.com | |
Affiliation | Nippon Boehringer Ingelheim Co., Ltd. |
Scientific contact | |
Name | Toru Tsunoda |
Address | ThinkPark Tower 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017, Japan Tokyo Japan 141-6017 |
Telephone | +81-120-189-779 |
medchiken.jp@boehringer-ingelheim.com | |
Affiliation | Nippon Boehringer Ingelheim Co., Ltd. |